The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
Zeno Equity Partners presents a detailed investment thesis on Danaher, their largest position, arguing it exemplifies their strategy of identifying companies with market power, sustainable high returns, and a founder's mindset focused on disciplined capital allocation. Danaher operates across three healthcare segments: Biotechnology (30% of revenues, 40% of profits), Diagnostics (40% of both), and Life Sciences (20% of profits), all benefiting from secular growth trends in aging populations, rising disease incidence, and technological advances. The Biotechnology segment, operating under the Cytiva brand, is described as the crown jewel with 88% recurring revenues and industry-leading 40% EBIT margins, particularly strong in chromatography purification with ~70% market share. Diagnostics demonstrates strong switching costs and vendor reputation barriers with 29% EBIT margins. The manager acknowledges mistakes in Life Sciences, particularly the Aldevron and Abcam acquisitions which have destroyed value. Despite recent headwinds from COVID normalization, biotech funding winter, China pricing pressure, and Trump administration policies, the manager believes these events have delayed rather than derailed returns. At a ~5% free-cash-flow yield with expected high-single-digit to low-double-digit earnings growth over the next decade, the manager views Danaher as offering compelling risk-adjusted returns.
Danaher is a high-quality business demonstrating market power and rewarding reinvestment opportunities across its Biotechnology, Diagnostics, and Life Sciences segments, driven by secular healthcare trends, strong switching costs, recurring revenue models, and the application of the Danaher Business System to drive continuous operational improvement.
The manager is confident that Danaher will continue to compound at very attractive returns for a very long time, despite disappointing total shareholder returns over the past five years. The manager believes external shocks have delayed rather than derailed the realization of shareholder returns, and the industry's eventual recovery is extremely likely given the strength of secular drivers. The manager expects the combined business can credibly deliver high-single-digit to low-double-digit earnings growth over the next decade.
As of Jul 25, 2026
Portfolio Manager and primary investment lead for Zeno.
Cristiano Souza and his team focus on identifying dominant businesses with strong moats, smart incentives, and resilient cultures. They seek companies that combine Market Power (strong competitive positioning), Reinvestment Opportunity (clear pathways to profitable growth), and Founder Mindset (management teams with owner-operator mentalities). The firm takes a contrarian approach, using market volatility as an opportunity to acquire exceptional businesses at attractive valuations. Their investment process involves deep fundamental analysis of approximately 300 companies, with the goal of building concentrated portfolios that can compound wealth over extended time horizons while managing downside risk through careful security selection and position sizing.
Zeno Equity Partners LLP
Managing Partner
High Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Zeno or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.
